Primary care physicians are often in the best position to identify and treat patients with AUD.
Joseph R. Volpicelli, MD, PhD
Advertisement
Joseph R. Volpicelli, MD, PhD, is a scientist-clinician with over 40 years of experience specializing in addiction psychiatry. He is executive director of the Institute of Addiction Medicine. His early work led to the approval of naltrexone to treat alcohol dependence; it was the first new medication to be FDA approved for this condition in nearly 50 years.
Articles by Joseph R. Volpicelli, MD, PhD
Teen drinking poses serious risks to adolescent health, affecting brain development and increasing addiction potential. There are effective strategies to address this issue.
Medication-assisted treatment (MAT) is an effective treatment for AUD, but it remains underutilized by the medical community.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Medical Economics
1
FDA-cleared neurostimulation device shows promise in reducing opioid, stimulant use, study finds
2
MJH Life Sciences acquires BPD Healthcare, expands its reach into hospital, health system space
3
More physicians are leaving Medicare, JAMA study finds
4
Increasing costs, declining value: U.S. health care at a crossroads
5
